Save

First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

PHASE1RECRUITING

For solid tumors and lymphoma, respectively: This study is to evaluate the safety and tolerability of EMB-07 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-07 will also be assessed.

Simpliy with AI

Study details:

This is a phase I, multicenter, open label, dose escalation, first in human study, designed to assess safety and tolerability, and to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose for EMB-07 in patient with locally advanced/metastatic solid tumors or relapse/refractory Lymphoma . Pharmacokinetics, pharmacodynamics, immunogenicity and response will also be assessed.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Willing and able to provide signed and dated informed consent prior to any study-related procedures and willing and able to comply with all study procedures.

Male or female, and aged ≥ 18 years

Treatment group A: Patients with histologically or cytologically locally advanced unresectable or metastatic solid tumors limiting to triple-negative breast cancer, lung adenocarcinoma, ovarian cancer, pancreatic cancer, colorectal cancer, gastric cancer, prostate cancer, bladder cancer, and uterus cancer. Treatment group B: Patients with histologically or cytologically relapse/refractory lymphoma limiting to chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL) and diffuse large B cell lymphoma (DLBCL).

Treatment group A: Standard therapies do not exist, or are no longer effective, or are not tolerable or accessible to the patient measurable or evaluable disease per RECIST V1.1. Treatment group B: Presence of at least one two-dimensional measurable lesion confirmed by imaging (CT or MRI) (either lymph nodes lesions with any long diameter > 1.5 cm or extranodal lesions with any long diameter > 1.0 cm); for CLL patients whose baseline imaging evaluation determined that no two-dimensional measurable lesions, their peripheral blood monoclonal B lymphocytes should be ≥ 5.0×10^9/L.

Patients must provide archival tumor samples, or a biopsy will be required if archival tumor sample is not available. Archival tumor sample must be taken ≤ 2 years prior to screening, otherwise a fresh tumor biopsy at screening is required.

ECOG performance status 0 or 1

Adequate organ function to participate in the trial.

Recovery from adverse events (AEs) related to prior anticancer therapy.

Exclusion criteria

Prior treatment with any agent targeting ROR1.

History of Grade 4 immune-related adverse events (irAEs) or irAEs requiring discontinuation of prior therapies.

Patient with primary central nervous system (CNS) malignancy or symptomatic CNS metastases. Patients with solid tumors with CNS metastases are eligible if they do not need to receive local radiation treatment at the discretion of investigator or if radiation therapy for CNS metastases is completed ≥ 4 weeks prior to study treatment.

Anticancer therapy or radiation < 5 half-lives or 4 weeks (whichever is shorter) prior to study treatment.

Abuse on alcohol, cannabis-derived products, or other drugs.

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2023-03-01

Primary completion: 2025-10-31

Study completion finish: 2026-03-31

Study type

TREATMENT

Phase

PHASE1

Trial ID

NCT05607498

Intervention or treatment

DRUG: EMB07

Conditions

• Advanced/Metastatic Solid Tumors
• Relapse/Refractory Lymphoma

Image related to Advanced/Metastatic Solid Tumors

Condition: Advanced/Metastatic Solid Tumors, Relapse/Refractory Lymphoma
DRUG: EMB07
Frankston, Victoria, Australia and more
Sponsor: EpimAb Biotherapeutics (Suzhou)Co., Ltd.

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Peninsula and South Eastern Haematology and Oncology Group

Research sites nearby

Select from list below to view details:

Peninsula and South Eastern Haematology and Oncology Group
Frankston, Victoria, Australia
One Clinical Research
Nedlands, Western Australia, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: EMB-07-Patients with solid tumor Patients with solid tumor will receive intravenous infusions of EMB-07 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is reached or all planned doses are administered.	DRUG: EMB07 EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI
EXPERIMENTAL: EMB07-Patients with lymphoma Patients with lymphoma will receive intravenous infusions of EMB-07 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is reached or all planned doses are administered.	DRUG: EMB07 EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Incidence and severity of adverse events as assessed by CTCAE V5.0.	Incidence and severity of AE.	Screening up to 30 days after the last dose.
Incidence of serious adverse events (SAE).	Incidence of SAE.	Screening up to 30 days after the last dose, or beyond 30 days if SAE is confirmed to be treatment related.
Incidence of dose interruptions.	Incidence of dose interruptions of EMB-07 during treatment as a measure of tolerability.	Screening up to 30 days after the last dose.
Dose intensity.	Actual amount of drug taken by patients divided by the planned amount.	Screening up to 30 days after the last dose.
The incidence of DLTs during the first cycle of treatment.	The dose limiting toxicities are based on drug related adverse events and are specifically defined in study protocol.	First infusion to the end of cycle 1. (each cycle is 28 days).

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Overall response rate.	Overall response rate measured by RECIST V1.1, iWCLL-2018, Lugano 2014	From the date of dosing untill the date of first documented progression or date of death from any casue, whichever case first, expected average 6 months.
Area under the serum concentration-time curve (AUC) of EMB-07.	Blood samples for serum PK analysis will be obtained (AUC).	Through treatment until EOT visit, expected average 6 months.
Maximum serum concentration (Cmax) of EMB-07.	Blood samples for serum PK analysis will be obtained (Cmax).	Through treatment until EOT visit, expected average 6 months.
Trough concentration (Ctrough) of EMB-07.	Blood samples for serum PK analysis will be obtained (Ctrough).	Through treatment until EOT visit, expected average 6 months.
Average concentration over a dosing interval (Css, avg) of EMB-07.	Blood samples for serum PK analysis will be obtained (Css,avg).	Through treatment until EOT visit, expected average 6 months.
Terminal half-life (T1/2) of EMB-07.	Blood samples for serum PK analysis will be obtained (T1/2).	Through treatment until EOT visit, expected average 6 months.
Systemic clearance (CL) of EMB-07.	Blood samples for serum PK analysis will be obtained (CL).	Through treatment until EOT visit, expected average 6 months.
Steady state volume of distribution (Vss) of EMB-07.	Blood samples for serum PK analysis will be obtained (Vss).	Through treatment until EOT visit, expected average 6 months.
Progression free survival (PFS) of EMB-07 as assessed by RECIST 1.1, iWCLL-2018, Lugano 2014	From the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, expected average 6 months.	Through treatment discontinuation: an average of 6 months
Incidence and titer of anti-drug antibodies stimulated by EMB-07.	Antibodies to EMB-07 will be assessed to evaluate potential immunogenicity.	Up to End of Treatment Follow Up Period (30 days after the last dose)

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma